Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

NGNE Sales of Investments

Cash received from selling or redeeming investments.

Neurogene Inc.NASDAQ: NGNE

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments grows, but more slowly than its trailing trend

Q1 FY2026 sales of investments of $130M rose 190.8% year over year, behind the +317.1% change in trailing-twelve-month sales of investments. Sequentially, it rose 86.1% from the prior quarter.

Context

  • Sales of investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +190.8% toward the trailing-twelve-month pace of +317.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$130M+86.1% QoQ
Last fiscal yearDec 2025
$284.7M+284.7% YoY
LTMMar 2026
$368.51M+317.1% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+190.8%——
1 year+284.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
284.7M USD
Year-over-year change
+284.7%

Sales of Investments vs competitors

How NGNE compares with its peers on the latest reported figures

  • NGNE's LTM Mar 2026 sales of investments of $368.51M is the 2nd largest of the 8 companies compared; the peer median is $194.74M.
  • Its year-over-year change of +317.1% is the 2nd highest of 6, against a peer median of -10.8%.
NGNE Competitors Peer median
Sales of Investments for NGNE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$459.84M -10.3%+5.2%2496.8%
NGNENeurogene Inc.LTM Mar 2026$368.51M +317.1%——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$286.12M -10.8%+33.3%324.2%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$265.4M -12.3%+50.2%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$194.74M -49.2%+73.7%533.6%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$117.42M +652.7%——
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$0 ——0.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$0 ——0.0%
Peer median (excluding NGNE) $194.74M-10.8%+41.8%324.2%

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Depreciation & Amortization947K3.2M3.3M3.25M3.09M
Deferred Income Tax00(105K)00
Stock-Based Compensation896K1.25M1.42M8.32M14.18M
Change in Working Capital1.6M(2.7M)(4.02M)(5.96M)268K
Accounts Receivables00000
Inventory00000
Accounts Payables2.98M(3.61M)667K(77K)627K
Other Working Capital(1.39M)912K(4.69M)(5.88M)(359K)
Other Non-Cash Items679K608K(15.69M)(1.07M)(4.37M)
Operating Cash Flow(46.4M)(52.82M)(51.42M)(70.6M)(77.17M)
Capital Expenditures(18.37M)(2.23M)(321K)(808K)(1.18M)
Acquisitions (Net)00000
Purchases of Investments000(198.45M)(269.51M)
Sales of Investments005M74M284.7M
Other Investing Activities0020.96M00
Investing Cash Flow(18.37M)(2.23M)25.64M(125.26M)14M
Debt Repayment0(1K)(29K)(52K)(61K)
Common Stock Issued287K73K92.34M189.59M30.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00168K(5.47M)0
Financing Cash Flow51.06M66.53M92.48M184.07M30.43M
Effect of Forex Changes00000
Net Change in Cash(13.71M)11.48M66.7M(11.79M)(32.74M)
Free Cash Flow(64.77M)(55.05M)(51.74M)(71.41M)(78.36M)

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.